Merck, FDA Dispute Safety Reviewer’s Estimate Of Vioxx-Related Events
Executive Summary
It is not possible to estimate the number of cardiovascular adverse events caused by Vioxx based on the data currently available, Merck CEO Ray Gilmartin maintained during the Nov. 18 Senate Finance Committee hearing on the drug's withdrawal
You may also be interested in...
Crestor, Serevent Safety Issues Push Vioxx Out Of Spotlight In Senate Hearing
FDA's focus following the Senate Finance Committee hearing on the Vioxx withdrawal is on defending the safety of five other drugs challenged by one of its safety reviewers
COX-2 Retrospective Study Prompts Review By FDA, Kaiser On Merck’s Vioxx
A retrospective study conducted on COX-2s and NSAIDs has prompted reviews by FDA and Kaiser Permanente on the use of Merck's Vioxx (rofecoxib)
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011